Technical Challenges and Recent Advances of Implementing Comprehensive ADMET Tools in Drug Discovery

This chapter contains sections titled: Introduction "A" Is the First Physiological Barrier That a Drug Faces "M" Is Frequently Considered Prior to Distribution Due to the "First-Pass" Effect "D" Is Critical for Correctly Interpreting PK Data "E": The Elimination of Drugs Should Not Be Ignored Metabolism- or Transporter-Related Safety Concerns Reversible CYP Inhibition Mechanism-Based (Time-Dependent) CYP Inhibition CYP Induction Reactive Metabolites Conclusion and Outlook Acknowledgments References